Picture loading failed.

Anti-CEACAM5;CD3E therapeutic antibody (Pre-made Cibisatamab biosimilar,Bispecific mAb with Domain Crossover) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cibisatamab, an investigational drug, is a bispecific antibody, which means it binds to two different proteins: one called CEACAM5 on the surface of some colorectal cancer cells and another on T cells called CD3.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-104-1mg 1mg Inquiry
GMP-Bios-ab-104-10mg 10mg Inquiry
GMP-Bios-ab-104-100mg 100mg Inquiry
GMP-Bios-ab-104-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CEACAM5;CD3E therapeutic antibody (Pre-made Cibisatamab biosimilar,Bispecific mAb with Domain Crossover)
INN Name Cibisatamab
TargetCEACAM5;CD3E
FormatBispecific mAb with Domain Crossover
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2017
Year Recommended2018
CompaniesRoche
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Colorectal cancer
Conditions DiscontinuedSolid tumours
Development Techna